In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis. Yeh HI, Hwang TC. Eur Respir J 2022;59.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yeh HI, Hwang TC. In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis. Eur Respir J 2022;59.
PMID: 35210304